Autopsy report · NCT01623232

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly

“FDA hold on the project”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

US Department of Veterans Affairs

Sponsor type

US federal agency

Conditions

Influenza Vaccines; Aged

Interventions

MAS-1 adjuvant and influenza HA antigen; standard dose, inactivated trivalent influenza vaccine (TIV)

Participants

0

Sites

4

Countries

United States

Trials that died the same way

• Safety of SP-420 in the Treatment of Transfusional Iron Overload
  “Study is on hold by FDA in the US.” (80% match in meaning)
• Perceval S Aortic Heart Valve Study- North America
  “FDA approval” (75% match in meaning)
• A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
  “Full clinical hold from FDA” (74% match in meaning)
• Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
  “FDA Clinical Hold” (74% match in meaning)
• OTX-14-002: Device Exposure Registry
  “On going discussions with FDA” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.